MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/trc2.70150

Медицинская библиотека · Alzheimer's & dementia (New York, N. Y.) · 2025

Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers.

Parks Anna L, Thacker Ayush, Dohan Daniel, Gomez Liliana A Ramirez, Gale Seth A, Johnson Kim G, Ritchie Christine S, Shah Sachin J, Paladino Joanna

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Anti-amyloid monoclonal antibodies (mAbs) slow cognitive decline in Alzheimer's disease but may cause amyloid-related imaging abnormalities (ARIA), which can rarely be disabling or fatal. This qualitative study investigates how clinicians communicate the benefits and risks of mAbs to patients and caregivers.

METHODS

Semi-structured interviews with clinicians who prescribe mAbs at seven academic medical centers. Hybrid inductive-deductive thematic analysis by interdisciplinary researchers.

RESULTS

In 27 clinician interviews (women [n = 17], White individuals [n = 19], neurologists [n = 17]), three themes emerged. First, clinicians varied in techniques used and concepts emphasized, including using analogies, discussing statistics, and emphasizing versus de-emphasizing risks. Second, patient contextual factors (e.g., comorbidities), hopes, and fears shaped communication. Third, clinician communication varied by training, personal style, and ambivalence. While clinicians honor patients' choices to pursue treatment, many do not "recommend" it (but may recommend against it).

DISCUSSION: Preliminary insights about how clinicians communicate tradeoffs can guide future shared decision-making interventions for mAbs.

HIGHLIGHTS: This qualitative study among 27 clinicians across seven academic medical centers examined how clinicians communicate with people with Alzheimer's disease about risks and benefits of anti-amyloid therapy, which can influence treatment decisions.Clinicians varied in what techniques they employed and how they portrayed risks and benefits, and whether they incorporated patients' values.They cited comorbidities, eligibility criteria fit, and degree of social support or family involvement in decisions as factors used in framing discussions, while fewer used patients' goals to guide discussion.The professional training, individual practice style, and personal sense of ambivalence of clinicians shaped conversations.These findings can guide future interventions to improve communication and shared decision-making.

Для цитирования: Parks Anna L, Thacker Ayush, Dohan Daniel, Gomez Liliana A Ramirez, Gale Seth A, Johnson Kim G, Ritchie Christine S, Shah Sachin J, Paladino Joanna. Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers.. Alzheimer's & dementia (New York, N. Y.). 2025. DOI: 10.1002/trc2.70150.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.